Richard Schilsky to Leucovorin
This is a "connection" page, showing publications Richard Schilsky has written about Leucovorin.
Connection Strength
1.642
-
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69.
Score: 0.504
-
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol. 1991; 28(1):69-73.
Score: 0.095
-
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990 Sep 05; 82(17):1411-5.
Score: 0.093
-
Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010 Jun; 7(6):318-25.
Score: 0.090
-
Inhibition of thymidylate synthase by the diastereoisomers of leucovorin. Cancer Chemother Pharmacol. 1990; 26(4):273-7.
Score: 0.088
-
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing. Cancer. 1989 Mar 15; 63(6 Suppl):1018-21.
Score: 0.084
-
Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. Anal Biochem. 1988 Feb 01; 168(2):398-404.
Score: 0.077
-
First-line treatment options for patients with metastatic colorectal cancer. Nat Clin Pract Oncol. 2004 Dec; 1(2):70-1.
Score: 0.062
-
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22; 90(6):1190-7.
Score: 0.059
-
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 2002 Mar 15; 20(6):1519-26.
Score: 0.051
-
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol. 2002 Jan; 13(1):87-91.
Score: 0.051
-
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001 Jul 12; 345(2):144-5; author reply 146.
Score: 0.049
-
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2000 Apr; 11(4):415-20.
Score: 0.045
-
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
Score: 0.039
-
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
Score: 0.037
-
Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. Stem Cells. 1996 Jan; 14(1):29-32.
Score: 0.033
-
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemother Pharmacol. 1993; 32(5):347-52.
Score: 0.027
-
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8.
Score: 0.024
-
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7.
Score: 0.022
-
High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987 Dec; 5(12):2017-31.
Score: 0.019
-
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7.
Score: 0.014
-
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. Clin Colorectal Cancer. 2002 Nov; 2(3):140-5.
Score: 0.013
-
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002 Apr; 13(4):566-75.
Score: 0.013
-
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63.
Score: 0.012
-
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs. 1999; 17(1):97-101.
Score: 0.010
-
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol. 1998 Sep; 9(9):1035-7.
Score: 0.010
-
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
Score: 0.009
-
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53.
Score: 0.005
-
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr; 6(4):618-26.
Score: 0.005